VALNEVA |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 2,810 EUR | -10,45 % |
|
-8,77 % | -40,47 % |
| 13.09. | Valneva nimmt 61 Millionen Euro durch Aktienplatzierung ein | MT |
| 13.09. | Valneva strebt 60 Millionen Euro aus Aktienemission an | MT |
Valneva Gruppe: Beziehungs-Chart
Private Unternehmen, die zur gleichen Gruppe wie VALNEVA gehören
| Unternehmen | Geschäftsführender Direktor |
|---|---|
Valneva Austria GmbH
 Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Frédéric Jacotot |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | - |
MarketScreener is also available in this country: United States.
Switch edition